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Abstract
Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is caused by
the production of low-affinity penicillin-binding protein 2a and β-lactamases,
which are encoded by mecA and blaZ, respectively. Expressions of the two key
genes are mutually regulated by MecI and BlaI. The aim of this study was to
design specific anti-mecR1 and anti-blaR1 deoxyribozymes and identify the
restoration of susceptibility in MRSA isolates with mecI or blaI or no deletions
by interfering with the mutual regulation of mecA and blaZ. 
Material and methods: Specific deoxyribozymes were designed by using the
program RNA structure 4.6. RNA substrates were obtained by transcription in
vitro and used to assess the target cleavage of DNAzymes. Transcription of
mecR1-mecA and blaR1-blaZ was analysed by real time RT-PCR. The susceptibility
of MRSA was tested.
Results: Specific deoxyribozymes showed efficient catalytic activity to each own
substrate mecR1 or blaR1 in vitro and caused the reduction of mecR1 and blaR1
transcription in vivo. Furthermore, simultaneous administration of two DNAzymes
to knockdown mecR1 and blaR1 resulted in increased susceptibility of all MRSA
strains tested in this study. 
Conclusions: These results demonstrated that combined use of the two specific
phosphorothioate deoxyribozymes could be a viable and promising strategy to
restore the susceptibility of almost all MRSA clinical isolates.
Key words: methicillin-resistant Staphylococcus aureus, mecR1, blaR1, phospho  ro  -
thioate deoxyribozyme.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA), a multidrug resistant
gram-positive bacterium, is one of the leading causes of hospital-associated
infections [1-3]. Vancomycin is one of the few drugs that have remained
effective against MRSA. However, recently the susceptibility of MRSA to
vancomycin has decreased and vancomycin is losing potency against MRSA
[4-6]. Linezolid (LZD) is typically used for the treatment of infections with
Gram-positive bacteria, including MRSA and VRSA in the United States [7,
8]. The emergence of linezolid (LZD)-resistant MRSA infections has been
reported from the USA, the UK, Brazil and Japan; it warns that we are
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Reversal of antibiotic resistance in MRSA by co-blockade
currently facing a growing shortage of effective
antibiotics [7, 9, 10]. The emergence of MRSA
resistant to the last-defence antibiotics (vancomycin
and linezolid) has created an urgent need to
discover alternative anti-MRSA approaches. 
The antibiotic resistance to β-lactam in MRSA is
mediated by mecA, which codes for the low-affinity
penicillin binding protein 2a (PBP 2a), an enzyme
working to allow cell-wall synthesis despite the
presence of β-lactam antibiotics [11]. Transcription
of mecA is regulated by a repressor, mecI, and
a sensor/transducer, mecR1 [12]. More than 90% of
staphylococcal isolates also produce β-lactamases,
the product of blaZ, and contain blaZ regulatory
sequences (blaI and blaR1) that are similar in
sequence and function to mecA regulators [13]. In
addition to regulating blaZ transcription, BlaI also
binds to mecA-mecR1 promoter-operator (P-O)
sequences and regulates their transcription. Co-
regulation of mecA by both MecI and BlaI has been
proved in clinical S. aureus isolates [14, 15].
The restoration of susceptibility in MRSA by
respective blocking mecR1  and  blaR1  is only
applicable to strains that harbour wild mecI or blaI
[16, 17]. But, mutations and deletions in mecI and
deletions of both mecI and mecR1 appear to be
common in clinical S. aureus isolates. It has been
shown that 96% of clinical isolates with mutant mecI
or with a deletion of mecI contain blaI, while the
isolates that do not contain blaI all have wild-type
mecI sequences [12, 18, 19]. The co-egulation of mecA
by both MecI and BlaI has been proved [14, 15, 20].
Therefore, MRSA must have at least one of the two
functional mecA regulators. This mutual regulation
of mecA by both MecI and BlaI plays a very important
role in antibiotic resistance of MRSA. 
Based on current understanding of the
mechanism of mecA co-regulation, the complete
restoration of β-lactam antibiotic susceptibility in
MRSA clinical isolates should be achieved by
simultaneous blockade of blaR1 and mecR1. In this
study, we explored the use of specific anti-mecR1
and anti-blaR1 phosphorothioated deoxyribozymes
(PS-DRz1694 and PS-DRz1366) and identified the
restoration of susceptibility in MRSA clinical isolates
with mecI deletion or blaI deletion or no deletions
by simultaneous blockage of MecR1 and BlaR1
mediated signal pathways. 
Material and methods 
Bacterial strains
Three clinical isolates, wild-type MRSA080302
with blaI only (ΔmecI-blaI), MRSA080305 with mecI
only (mecI-ΔblaI) and MRSA080309 with both mecI
and blaI (mecI-blaI) were obtained from cultures of
sputum and catheter samples from patients in
Xijing Hospital (Xi’an, China). MSSA type strain
ATCC 29213 was used as a positive control.
Deoxyribozyme design
The program RNAstructure 4.6 was used to
design anti-mecR1 and anti-blaR1 10-23 deoxy  ri  bo  -
zymes. The deoxyribozymes were synthesized by
Shanghai Sangon Biological Engineering Technology
and Services (Shanghai, China), and were partly
phosphorothioated (Table I).
In vitro transcription
The two gene fragments (mecR1 and blaR1) were
constructed into pGEM-T vector by Shanghai
Sangon Biological Engineering Technology and
Services (Shanghai, China), respectively. The two
constructed plasmids were linearized by NcoI
(Toyobo, Japan). The RiboMAX large scale production
system (Promega, Madison, WI, USA) was used for
the transcription under the guide of the
manufacturer’s instructions. The resulting RNA was
purified and concentrated with sodium acetate and
chilled ethanol. 
PS-DRzyme cleavage assay
To assess the target cleavage of DNAzymes, RNA
substrates and DNAzymes were mixed with 20 μl
of reaction buffer (50 mM Tris, pH 8.0, 20 mM
MgCl2, 0.01% SDS) at 37°C. The reaction was
quenched at various time intervals with 50 mmol/l
EDTA and the samples were denatured for 10 min
at 70°C, and then the uncleaved substrate and
products were resolved by electrophoresis on 3%
denaturing agarose gel. The gel was incubated in
1×SYBR Gold nucleic acid gel staining solution
(Invitrogen, Carlsbad, CA, USA) for 40 min. The band
densities were quantitated by the Alpha Imager
system (Alpha Innotech, California, USA). The
DNAzyme sequence (5'-3')a RNA substrate sequence (5'-3') Cleavage site (nt)
DRz1694 ATTCGCAggctagctacaacgaTGTCTTCGCCTT AAGGCGAAGACAAUGCGAAU 1694
DRz1366 CTTGAGTTGAGggctagctacaacgaCGCAGTAAT AUUACUGCGACUCAACUCAAG 1366
DRz5491 CATAGGCAcgcatgctaacacgaTGTCCGCTTCT
aThe 10-23 catalytic motifs of PS-DRzymes are indicated in lower case. The sequences of PS-DNAzymes for the target binding domains are in
uppercase, which are designed to be complementary to mecR1 and blaR1 respectively and were all modified with phosphorothioates to increase
nuclease resistance
Table I. Summary of sequences and cleavage sites of DNAzymes used416 Arch Med Sci 3, June / 2011
fraction of substrates cleaved by DNAzymes was
calculated and plotted against time. All reported
kinetic values are means ± SD of at least three
independent experiments. Vmax and KM values were
determined from the y intercept and slope,
respectively, of the best-fit line to a Lineweaver-
Burke plot of 1/V vs. 1/[S].
PS-DRzyme delivery and real time RT-PCR
Staphylococcus aureus was cultured overnight and
1 ml of culture was transferred to 100 ml broth
medium. The medium was incubated at 37°C until
the OD600 reached 0.55-0.65. Cells were centrifuged
at 6000 rpm at 4°C for 10 min. The cell pellet was
washed twice by re-suspending in 100 ml of sterilized,
ice-cold water and centrifuging at 6000 rpm 
at 4°C for 10 min. Then the pellet was washed an
additional four times with 40, 10, 2 and 1 ml of 10%
cold glycerol. Finally, the pellet was resuspended in
1 ml of 10% cold glycerol, distributed into 50 ml
aliquots. 10 mg/l anti-mecR1 phosphorothioated
deoxyribozyme1694 (PS-DRz1694) or 10 mg/l anti-
blaR1 phosphorothioated deoxyribozyme1366 
(PS-DRz1366) was introduced into competent MRSA
strains by electroporation under the following
conditions: 25 μf, 900 V, 200 Ω, time constant 3.6-
4.2 ms. 
The culture of S. aureus was centrifuged at 
5000 rpm for 10 min at 4°C and supernatant was
decanted. The cell pellet was suspended in 100 μl
of lysis solution (50 mM Tris-HCl pH 7.5, 5 mM EDTA
pH 8, 50 mM NaCl, 10 mM Tris) with 300 μg of
lysozyme (Sigma) and 5 μg of lysostaphin (Sigma)
for 30 min at room temperature. The total RNA was
extracted from the bacterial lysis with Trizol reagent
(Invitrogen, Carlsbad, CA, U.S.A.) following the
manufacturer’s instructions, and the RNA samples
were treated with DNase I to remove any genomic
DNA contamination. The total RNAs were extracted
from the bacterial lysis with Trizol reagent
(Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s instructions. The cDNA was
synthesized by reverse transcription from 1 μg of
each RNA sample using SuperScript III reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). The
nucleotide sequences for various primers were
listed (Table II). PCR was run in a DNA Engine
Opticon (MJ Research, Waltham, USA) using SYBR
Green I. PCR reagents consisted of: 12.5 μl of SYBR
Premix Ex TaqTM (TaKaRa, DRR041S, Japan), 
0.5 μl of 50× ROX Reference Dye (TaKaRa,
DRR041S, Japan), 0.75 μl of each primer (10 μM)
and 1 μl of sample cDNA, in a final volume of 
25 μl. Thermal cycling conditions: initial dena  -
turation step at 95°C for 5 min, 50 cycles at 95°C
for 10 s, 56°C for 20 s and 72°C for 20 s.
The cDNA of the control group was fold series
diluted and the analysis was performed as follows:
for each sample, the difference in Ct values (ΔCt) was
calculated for target genes subtracting Ct for the
reference RNA. ΔCt = Ct(target gene) – Ct(16SrRNA). Relative
expression of target genes mRNA was calculated
using the comparative Ct method as previously
described [17]. The ΔΔCt values were calculated by
the following equation: ΔΔCt = ΔCt(treatment) –
ΔCt(control). The mean of these ΔΔCt measurements
was then used to calculate expression of the test
gene (2–ΔΔCt) relative to the reference gene, 16SrRNA,
and normalized to the untreated control as follows:
relative expression = 2–ΔΔCt. The evaluation of 2–ΔΔCt
indicates the fold change in gene expression relative
to the untreated control.
Susceptibility testing
After electroporation, the cells were recovered
in preheated broth medium containing 6 mg/l of
oxacillin at 37°C with 150 rpm agitation for 1 h.
The growth determination was carried out as
follows: The cells were diluted 104-108 times. Fifty
microlitres of diluted cells were spread onto plates
of Mueller-Hinton agar containing 6 mg/l of
oxacillin, and the plates were incubated for 48 h
at 35°C. The colonies were counted for plates with
> 10 and < 500 colonies and the total number of
CFU (colony forming units) per sample was
determined by correcting the colony count for the
dilution factor. 
To determine the growth curves for MRSA, 100 μl
of cell dilution were added to the wells of a 96-well
microtitre plate, and the plate was incubated at
35°C with agitation at 120 rpm. The optical density
(OD600) of each well was measured with a micro  -
plate reader (Bio-Rad Laboratories, Tokyo, Japan) 
at different time points.
According to the guidelines of the Clinical and
Laboratory Standards Institute (CLSI), the minimum
inhibitory concentrations (MICs) of oxacillin for
MRSA080302, MRSA080305, MRSA080309 and
MSSA ATCC29213 were determined by the standard
broth dilution method [17, 21]. 
Statistical analysis
Values are expressed as mean ± SD. One-way
ANOVA analysis followed by Student-Newman-
Keuls (SNK) test was performed for CFU and RNA
expression variables. A value of p < 0.05 was
considered statistically significant.
Results
Design and characterization of anti-mecR1 and
anti-blaR1 deoxyribozyme 
Based on analysis of target mRNA secondary
structures by the program RNAstructure 4.6, two
optimized deoxyribozymes, PS-DRz1694 targeting
Zheng Hou, Ying Zhou, Haifang Wang, Hui Bai, Jingru Meng, Xiaoyan Xue, Xiaoxing LuoArch Med Sci 3, June / 2011 417
Reversal of antibiotic resistance in MRSA by co-blockade
mecR1  and PS-DRz1366 targeting blaR1, were
generated. The design parameters of ΔGoligo-oligo,
ΔGoligo-self, ΔGduplex, ΔGoverall and Tm for PS-DRz1694
were –2.1, 0, –28.0, –17.3 kcal/mol, 75.3°C,
respectively. The same parameters for PS-DRz1366
were –3, 0, –25.2, –20.6 kcal/mol and 73.9°C.
The target binding domain sequences of 
PS-DRz1694 and PS-DRz1366 are shown in Table I;
they were designed to be complementary in
sequence to nt 1682~1701 of mecR1 (GenBank
accession no. X63598) and nt 1357~1377 of blaR1
(GenBank accession no. M62650) in S. aureus
respectively. Both PS-DRz1694 and PS-DRz1366 are
34-mers consisting of a central 10-23 catalytic core
domain (15 nts) flanked by target-specific binding
arms (19 nts), which were modified with phospho  -
rothioates to increase nuclease resistance.
Mismatched sequences PS-DRz5491 had been
randomly aligned with the same number of bases,
in which binding arms were also phospho  ro  -
thioated. 
In vitro cleavage of mecR1 and blaR1 
The kcat and KM values for PS-DRz1694 or 
PS-DRz1366 were determined under a wide range
of single turnover conditions with the respective
mecR1 or blaR1 RNA substrates. The cleavage
products of mecR1 and blaR1 were obtained
respectively (Figures 1 A1, 1 A2). Both DNAzymes
exhibited similar catalytic kinetics and the 
PS-DRz1694 or PS-DRz1366 was able to cleave
nearly 90% of mecR1 or blaR1 within 60 min in
a cell-free system respectively (Figures 1 B1, 1 B2).
Cleavage of mecR1 RNA by PS-DRz1694 proceeded
with the efficiency of kcat/KM of 4.55 × 106 M–1
min–1 and Vmax at 3.316 nM/min. PS-DRz1366
showed kcat/KM value at 6.22 × 106 M–1 min–1 and
Vmax at 3.598 nM/min (Figure 1 C). These results
indicated that anti-mecR1 PS-DRz1694 and anti-
blaR1 PS-DRz1366 could effectively cleave
RNAmecR1 and RNAblaR1, respectively, and the
cleavage efficiency of PS-DRz1366 was higher
than that of PS-DRz1694.
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Figure 1. In vitro cleavage activities of PS-DRz1694 and PS-DRz1366. (A1) Cleavage of RNAsmecR1 by PS-DRz1694. 
(A2) Cleavage of RNAsblaR1 by PS-DRz1366. Time course of the cleavage of in vitro, transcribed mRNAs of mecR1 and
blaR1 cleaved by PS-DRz1694 (B1) and PS-DRz1366 (B2), respectively. (C) Kinetic parameters of the PS-DRz1694 and 
PS-DRz1366 reactions
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PS-DRzymes Vmax [nMmin–1] KM [nM] kcat [min–1] kcat/ KM [M–1min–1]
PS-DRz1694 3.316 26.682 0.1215 4.55 x 106
PS-DRz1366 3.598 21.176 0.1318 6.22 x 106418 Arch Med Sci 3, June / 2011
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Figure 2. Comparison of expression of antibiotic resistant genes in three clinical MRSA isolates, MRSA080302 (ΔmecI-
blaI), MRSA080305 (mecI-ΔblaI) and MRSA080309 (mecI-blaI). Relative mRNA expression of mecR1 (A), blaR1 (B),
mecA (C), and blaZ (D)
*p < 0.05,**p < 0.01 vs. control, Δ indicates that the repressor is absent
150
120
90
60
30
0
ΔmecI-blaI mecI-ΔblaI mecI-blaI
R
e
l
a
t
i
v
e
 
m
e
c
A
e
x
p
r
e
s
s
i
o
n
 
[
%
]
C
150
120
90
60
30
0
ΔmecI-blaI mecI-ΔblaI mecI-blaI
R
e
l
a
t
i
v
e
 
b
l
a
Z
e
x
p
r
e
s
s
i
o
n
 
[
%
]
D
Control             PS-DRz1694             PS-DRz1366 Control             PS-DRz1694             PS-DRz1366
150
120
90
60
30
0
ΔmecI-blaI mecI-ΔblaI mecI-blaI
R
e
l
a
t
i
v
e
 
m
e
c
R
1
e
x
p
r
e
s
s
i
o
n
 
[
%
]
A
150
120
90
60
30
0
ΔmecI-blaI mecI-ΔblaI mecI-blaI
R
e
l
a
t
i
v
e
 
b
l
a
R
1
e
x
p
r
e
s
s
i
o
n
 
[
%
]
B
Control             PS-DRz5491             PS-DRz1694 Control             PS-DRz5491             PS-DRz1366
Real-time quantitation assays for mecA/blaZ
and mecR1/blaR1 transcription
To ascertain whether the blockage of mecR1 or
blaR1 also inhibits the expression of downstream
gene mecA/blaZ in MRSA isolates, MRSA080302 or
MRSA080305 with mecI or blaI deletions, and
MRSA080309 with wild types of mecI/blaI, the anti-
mecR1 PS-DRz1694 or anti-blaR1 PS-DRz1366 was
applied to each clinical isolate of MRSA respectively.
The transcriptions of mecR1/blaR1 and mecA/blaZ
were detected by real-time PCR. 
Compared with the control groups, the relative
transcription of mecR1  in three MRSA isolates
(MRSA080302, MRSA080305 and MRSA080309) was
decreased to 33%, 21%, and 18% of the control values
by PS-DRz1694 treatment, respectively (Figure 2 A).
And the relative transcription of blaR1 of those MRSA
isolates was decreased to 14%, 31%, and 9% of the
control values by PS-DRz1366 treatment, respectively
(Figure 2 B). These results demonstrated that mecR1
or blaR1 was blocked specifically by PS-DRz1694 
or PS-DRz1366 res  pec  tively.
Compared with the control group, anti-blaR1
PS-DRz1366 treatment caused 85% reduction for
mecA expression and 72% of reduction for blaZ
expression respectively in the mecI deleted strain
MRSA080302 (Figures 2 C, 2 D). However, the
expression of mecA and blaZ was not altered by
treatment with anti-mecR1 PS-DRz1694 alone in
MRSA080302 (Figures 2 C, 2 D). A similar inhibition
pattern on mecA/blaZ expression was observed in
the blaI deleted strain MRSA080305 after anti-
mecR1 PS-DRz1694 treatment. The expression of
mecA and blaZ in blaI deleted strain MRSA080305
showed 56% (Figure 2 C) and 32% (Figure 2 D)
reduction after PS-DRz1694 treatment. But the
expression of mecA and blaZ in MRSA080305 was
not altered by PS-DRz1366. Meanwhile, the
expression of blaZ  or  mecA  in MRSA080309,
a strain harbouring wild type mecI-blaI, was
inhibited only by PS-DRz1366 or PS-DRz1694
respectively (Figure 2 C, 2 D). 
Restoration of susceptibility to antibiotic 
in MRSA clinical isolates 
We found that the downregulation of mecR1 and
blaR1 by combined administration of anti-mecR1 Arch Med Sci 3, June / 2011 419
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PS-DRz1694 and anti-blaR1 PS-DRz1366 correlated
with the restoration of susceptibility of MRSA clinical
isolates to β-lactam antibiotics. The numbers 
of MRSA080302 colonies in PS-DRz1366 alone or 
PS-DRz1366 and PS-DRz1694 combination-treated
cultures on Mueller-Hinton agar containing oxacillin
(6 μg/ml) were reduced by 103- to 104-fold,
respectively (Figure 3). The 102- to 103-fold reduction
of MRSA080305 colonies was achieved by treatment
of either PS-DRz1694 alone or PS-DRz1694 and 
PS-DRz1366 combination (Figure 3). In MRSA080309,
oxacillin gave rise to a 104- or 105-fold striking
reduction in CFU after PS-DRz1694 or PS-DRz1366
treatment, respectively (Figure 3). The combination
of these two DNAzymes caused stronger effects on
CFU reduction and led to a synergistic effect on the
reversal of antibiotic resistance of MRSA080309
(Figure 3). 
In liquid medium containing oxacillin (6 mg/l),
the growth of PS-DRz1366-treated MRSA080302
and PS-DRz1694-treated MRSA080305 cells was
inhibited, respectively (Figures 4 A, 4 B). However,
the growth of MRSA080302 was not influenced by
treatment with either PS-DRz1694 alone or
mismatched PS-DRz5491 (Figures 3, 4 A). Similarly,
the growth of MRSA080305 was not affected by
treatment with either PS-DRz1366 alone or
mismatched PS-DRz5491 (Figures 3, 4 B). The growth
of MRSA080309 was inhibited by treatment 
with either PS-DRz1694 or PS-DRz1366 alone.
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12
11
10
9
8
7
6
5
4
ΔmecI-blaI mecI-ΔblaI mecI-blaI
L
o
g
 
C
F
U
/
m
l
Figure 3. Effects of PS-DRz1694 or PS-DRz1366 on the
growth of three clinical MRSA isolates – MRSA080302
(ΔmecI-blaI), MRSA080305 (mecI-ΔblaI) and
MRSA080309 (mecI-blaI). DRz1366 group, DRz1694
group and DRz1694 + DRz1366 group vs. control
*p < 0.05, **p < 0.01; DRz1694 + DRz1366 group vs.
DRz1694 group, +p < 0.05, ++p < 0.01; DRz1694 +
DRz1366 group vs. DRz1366 group, #p < 0.05, 
##p < 0.01. The following are different treated groups:
control, 10 mg/l PBS; DRz5491, 10 mg/l DRz5491;
DRz1694, 10 mg/l DRz1694; DRz1366, 10 mg/l
DRz1366; DRz1694 + DRz1366, 10 mg/l DRz1694 + 10
mg/l DRz1366. The data are shown as mean ± SD for
8 samples
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Figure 4. Effects of PS-DRz1694 or PS-DRz1366 on the
growth of three clinical MRSA isolates in liquid
medium (6 mg/l of oxacillin). The growth of different
groups was monitored by using OD600 measurements.
(A) The OD600 value of MRSA080302 in different
treated groups. (B) The OD600 value of MRSA080305
in different treated groups. (C) The OD600 value of
MRSA080309 in different treated groups. The
following are different treated groups: control, 10 mg/l
PBS; DRz5491, 10 mg/l DRz5491; DRz1694, 10 mg/l
DRz1694; DRz1366, 10 mg/l DRz1366; DRz1694 +
DRz1366, 10 mg/l DRz1694 + 10 mg/l DRz1366. The
data are shown as mean ± SD for 5 samples
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PS-DRz1366 resulted in the more significant
restoration of susceptibility of MRSA080309 to
oxacillin (Figures 3, 4C).
Meanwhile, PS-DRz1366 reduced the MIC 
of oxacillin for MRSA080302 (ΔmecI-blaI) from 
1,024 mg/l to 1 mg/l and PS-DRz1694 reduced 
the MIC of oxacillin on MRSA080305 (mecI-ΔblaI)
from 512 mg/l to 2 mg/l (Table III), both of which
are within the oxacillin sensitivity range for the
MRSA strains on the basis of the interpretive criteria
recommended by the CLSI, representing the 
full restoration of MRSA susceptibility to oxacillin.
The PS-DRz1366 or PS-DRz1694 alone did 
not alter the MIC of oxacillin for MRSA080305 
or MRSA080302 respectively (Table III). On
MRSA080309 strain harbouring wild type mecI/blaI,
PS-DRz1694 or PS-DRz1366 only reduced the MIC
of oxacillin from 1024 mg/l to 512 mg/l or from 1024
mg/l to 256 mg/l, respectively, which indicated
a partial restoration of susceptibility of
MRSA080309 to oxacillin. However, the combined
administration of PS-DRz1694 and PS-DRz1366 to
MRSA080309 caused a dramatic reduction on MIC
of oxacillin from 1024 mg/l to 1 mg/l, which
represented a full restoration of MRSA susceptibility
to oxacillin. In addition, the MICs of oxacillin on
MRSA080302 and MRSA080305 were decreased
from 1024 mg/l to 2 mg/l and from 512 mg/l to 
4 mg/l respectively under DRz1694 and DRz1366
combination treatment (Table III). 
Discussion
Methicillin-resistant Staphylococcus aureus is
resistant to all commercially available β-lactam
antibiotics and also represents a therapeutic
challenge, because effective therapeutic options
are becoming limited. The expression of antibiotic-
resistant genes mecA and  blaZ is involved in
antibiotic resistance of MRSA. Inhibition of bacterial
gene expression by the antisense approach has
been proposed as a promising strategy for bacterial
infection therapy through targeting specific genes
in bacteria [22-25]. Especially, catalytic oligodeo  -
xynucleotides are valuable tools to downregulate
the expression of resistant genes in a sequence-
specific manner and have been widely applied in
vitro and in vivo [26, 27].
In this study, we designed two deoxyribozymes
(PS-DRz1694 and PS-DRz1366) specifically targeting
mecR1 and blaR1 to restore susceptibility of clinical
MRSA isolates. First, the consistency of catalytic
activities of deoxyribozyme were demonstrated in
vitro and in vivo. With the increase of the reaction
time, the substrate mecR1 or blaR1 was cleaved 
into two cleavage products by the two DNAzymes
in vitro, respectively. Then DNAzymes were
electroporated into bacteria and the transcription
levels of mecR1  and  blaR1  were tested. The
repression of mecR1 or blaR1 was observed in all
MRSA strains treated by anti-mecR1 or anti-blaR1
DNAzyme respectively and showed specific catalytic
activity of deoxyribozyme in vivo.
However, the inhibitory efficiency on the mec
regulated mecA or bla regulated blaZ expression
was different in all MRSA strains. In the blaI deleted
strain MRSA080305 (mecI-ΔblaI), expression of both
mecA and blaZ was decreased significantly by anti-
mecR1 DNAzyme PS-DRz1694, but not by anti-blaR1
DNAzyme PS-DRz1366. Meanwhile in mecI deleted
strain MRSA080302 (ΔmecI-blaI), anti-mecR1
DNAzyme PS-DRz1366 caused significant reduction
of mecA and blaZ expression. In mecI-blaI non-
mutation strain MRSA080309, PS-DRz1366 or 
PS-DRz1694 only cleaved its target gene, blaR1 or
mecR1, and thereafter led to blaZ  or  mecA
repression respectively. The outcomes indicated
identically that mecR1 cleaved by PS-DRz1694 could
prevent the cleavage of MecI.  Similarly,  blaR1
cleaved by PS-DRz1366 could merely prohibit the
cutting of BlaI. So, we demonstrated that mecR1
and blaR1 are specific for their own homologous
repressor and are not interchangeable in repressor
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Genes Primers Primer sequence (5’-3’) Location [bp] Size [bp] Annealing temperature [°C]
mecR1 Forward acacgacttcttcggttag 218-236 336 58
Reverse gtacaatttgggatttcact 534-553
mecA Forward gcaatcgctaaagaactaag 553-572 225 58
Reverse aatgggaccaacataaccta 758-777
blaR1 Forward acaatgaagtagaagccgatagat 719-742 489 55
Reverse gtcggtcaagtccaaaca 1207-1190
blaZ Forward agagatttgcctatgcttca 311-330 461 56
Reverse agtatctccgcttttattattt 771-750
16SrRNA Forward gttattagggaagaacatatgtg 446-468 750 55
Reverse ccaccttcctccggtttgtcacc 1195-1173
Table II. Oligonucleotide primers used for PCRArch Med Sci 3, June / 2011 421
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cleavage. Furthermore, PS-DRz1366-mediated
uncleavage of MecI could effectively inhibit the
expression of not only mecA but also blaZ in
MRSA080302. It is the same for PS-DRz1694 in
MRSA080305. Therefore, we demonstrated that
mecA and blaZ can be mutually regulated by either
MecI or BlaI, which might be the result of the fact
that MecI and BlaI are almost identical and are
interchangeable in repression of target gene
transcription. 
Further investigations on bacteria growth and
susceptibility in the presence of oxacillin demon  -
strated a high correlation between targeted gene
repression and MRSA growth suppression. The anti-
mecR1 PS-DRz1694 caused repression of mecA and
blaZ in MRSA080305. Also, reduction of CFU and
inhibition of the growth curve were observed in
MRSA080305, but not in mecI  deleted strain
MRSA080302. In contrast, anti-blaR1 PS-DRz1366
effectively inhibited the expression of mecA and blaZ
in MRSA080302, and only inhibited MRSA080302
growth. A high correlation between the down-
regulation of blaR1/mecR1 and suppression of MRSA
growth was also observed in non-mecI-blaI
mutation strain MRSA080309 after treatment with
PS-DRz1366 or PS-DRz1694 respectively. As both
mecR1-mecI-mecA and blaR1-blaI-blaZ systems play
roles in induction of antibiotic resistance in MRSA
[13, 15, 28], blockade of each signal pathway only
partially restored the susceptibility. The combination
treatment of PS-DRz1694 and PS-DRz1366 on
MRSA080309 resulted in synergic effects on
susceptibility restoration to oxacillin. 
It is particularly encouraging that MICs of
oxacillin to MRSA080302, MRSA080305 and
MRSA080309 were fully restored to values within
the sensitivity defining range by PS-DRz1366, 
PS-DRz1694 and combined administration of these
two DNAzymes, respectively (Table III). Although
PS-DRz1366 and PS-DRz1694 only worked in certain
MRSA strains, more importantly, we demonstrated
that simultaneous administration of the two
DNAzymes to knockdown mecR1 and blaR1 resulted
in increased susceptibility of all MRSA strains tested
in this study. This is thought to be accomplished by
reducing the level of mecA and blaZ. When the
levels of mecA and blaZ are lowered, the MRSA is
not protected against oxacillin and the MRSA is
killed.
The results of the present study indicate that co-
blockade of blaR1-blaZ and mecR1-mecA signal
pathways without detecting mecI or blaI mutation
is a feasible strategy to restore the susceptibility of
MRSA clinical strains to existing β-lactam
antibiotics.
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